COMORBIDITY AND CAUSE OF DEATH IN THE DIFFERENT VARIANTS OF SARS-COV-2 VIRUS, WITH CONTRIBUTION OF 20 AUTOPSY CASES
DOI:
https://doi.org/10.58395/m27hv064Keywords:
COVID-19, SARS-CoV-2, thrombosis, co-morbidities, InfarctionAbstract
Analyzing the clinical and epidemiological data of COVID-19 suggests that specific comorbidities increase the risk of infection leading to worse lung injury and an even higher risk of death. The most common comorbidities reported up till now are hypertension, cardiovascular diseases, and diabetes.
Aim to study: The design of the study includes comorbidity of patients and cause of death in alfa, delta, and omicron variants of SARS-CoV-2 virus, histological changes in the lungs, thrombotic complications of coronavirus infection and laboratory tests concerning thrombotic changes.
Materials and Methods: We systematically evaluated 20 autopsies of patients deceased by COVID-19 infection. Collecting data was from February 28th, 2020, until June 2022. The cases were diagnosed with a PCR (Polymerase Chain Reaction) test and a rapid antigen test. 10 of the deceased patients were from the first, second, third, and fourth wave (I group) infected predominantly with the alfa and delta variants of coronavirus (from March 2020 until October 2021), and 10 patients infected after that date with predominantly the omicron variant (II group).
Results: Most patients were over 50 years of age with multiple co-morbidities (28-88, average 63.9). Post-mortem case studies have shown Arterial hypertension in 80% (I/II gr), 60%/90% of patients with chronic ischemic heart disease, chronic and acute ischemic brain disease in 30%/10%, atherosclerosis, 60%/90%, diabetes mellitus 30%/40%, obesity stage III, 100%/95%). Clinical laboratory studies, in connection with thrombotic complications, revealed the increased value of creatine kinase, fibrinogen, D-dimers, and CRP. Lymphopenia was observed in 60%.
All of the cases with COVID-19 viral desquamative pneumonia, at different stages, developed vascular thrombosis in medium-sized pulmonary vessels. Two patients developed pulmonary thromboembolism. We established 5 patients with generalized thrombosis. Three patients were complicated by infarcts in the brain, kidney, and spleen.
Conclusion: The autopsies revealed a consistent pattern of pulmonary alveolar damage and generalized vascular/thrombotic disease in patients with frequent co-morbidities. The high frequency of generalized thrombotic complications was observed in predominant alfa and delta variants of the infection, while in the group with the omicron prevailing variant, the lung lesions were dominant, without extrapulmonary thrombotic complications, which we explain by the effective antithrombotic therapy. Major complications in these patients were secondary bacterial infection, sepsis, and respiratory distress syndrome.
Downloads
References
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. https://doi.org/10.1056/NEJMoa2001017
Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020; 98: 219–27. HTTPS://DOI.OR/10.1016/j.kint.2020.04.003
Li Y, Xiao SY. Hepatic involvement in COVID-19 patients: pathology, pathogenesis, and clinical implications. J Med Virol. 2020; 92:1491–4. https://doi.org/10.1002/jmv.25973
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020; 15; 413:116832. https://doi.org/10.1016/j.jns.2020.116832
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020; 75: 2950–73. https://doi.org/10.1016/j.jacc.2020.04.031.
Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet 2020; 396: 320–32. https://doi.org/10.1016/S0140-6736(20)31305-2
Borczuk AC, Salvatore SP, Seshan SV. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Modern Pathology 2020; 33:2156–2168. https://doi.org/10.25040/ntsh2022.02.02
Deshmukh V, Motwani R, Kumar A, Kumari C, Raza K. Histopathological observations in COVID-19: a systematic review. J Clin Pathol. 2021; 74(2):76-83. https://doi.org/10.1136/jclinpath-2020-206995
Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, et al. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series. Ann Intern Med. 2020; 173(5):350-361. https://doi.org/10.7326/M20-2566
Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A, et al. Pulmonary pathological features in coronavirus-associated severe acute respiratory syndrome (SARS-CoV-2). J Clin Pathol. 2004; 57(3): 260-265. https://doi.org/10.1136/jcp.2003.013276
Ahmed S, Zimba O, Gasparyan AJ. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clinical Rheumatology 2020; 39:2529–2543. https://doi.org/10.1007/s10067-020-05275-1
Hariri LP, North CM, Shih AR, Israel RA, Maley JH, Villalba JA, et al. Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza Q1 A Systematic Review. Chest. 2021; 159(1): 73-84. https://doi.org/10.1016/j.chest.2020.09.259
Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage: the role of oxygen, shock, and related factors. A review. Am J Pathol. 1976; 85(1): 209-228. PMC203255415.
Marshall RP, Bellingan G, Webb S, Puddicombe A, Goldsack N, McAnulty RJ, et al. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med. 2000; 162 (5): 1783-1788. https://doi.org/10.1164/ajrccm.162.5.2001061
Hariri L, Hardin CC. COVID-19, angiogenesis, and ARDS endotypes. N Engl J Med. 2020; 383(2): 182-183. https://doi.org/10.1056/nejme2018629
Zeng Z, Xu L, Xie XY, Yan HL, Xie BJ, Xu WZ, et al. Pulmonary pathology of early-phase COVID-19 pneumonia in a patient with a benign lung lesion. Histopathology 2020; 77(5):823-831. https://doi.org/10.1111/his.14138
Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 2020;172(9): 629-632. https://doi.org/10.7326/M20-0533
Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020;77(2):198-209. https://doi.org/10.1111/his.14134
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420–2. https://doi.org/10.1016/S2213-2600(20)30076-X
Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020; 173:268–77. https://doi.org/10.7326/M20-2003
Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020; 323: 2329–30. https://doi.org/10.1001/jama.2020.6825
Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020; 33:1007–14. https://doi.org/10.1038/s41379-020-0536-x
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–18. https://doi.org/10.1016/S0140-6736(20)30937-5
Xing YH, Ni W, Wu Q, Li WJ, Li GJ, Wang WD, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. J Microbiol Immunol Infect. 2020; 53: 473–80. https://doi.org/10.1016/j.jmii.2020.03.021
Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18: 1094–1099. https://doi.org/10.1111/jth.14817
Ahmed I, Azhar A, Eltaweel N, Tan BK. First COVID-19 maternal mortality in the UK associated with thrombotic complications. Br J Haematol 2020; 190: e37–e38. https://doi.org/10.1111/bjh.16849
Johns Hopkins University & Medicine. Coronavirus resource center [Internet]. 2023. Available at: https://coronavirus.jhu.edu/map.html.
Justino DCP, Silva DFO, da Silva Costa KT, Morais TNB, Andrade FB. Prevalence of comorbidities in deceased patients with COVID-19: a systematic review. Medicine 2022; 101: 38(e30246). https://doi.org/10.1097/MD.0000000000030246
Zhou B, Lu Y, Hajifathalian K, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 populationbased studies with 4 4 million participants. Lancet. 2016; 387: 1513–30.
Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021. Prev Chronic Dis 2021; 18: E66. https://doi.org/10.5888/pcd18.210123 PMID: 34197283.
Clark A, Jit M, Warren-Gash C, et al. Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modeling study. Lancet Glob Health 2020; 8:e1003-17. https://doi.org/10.1016/S2214-109X(20)30264-3 PMID: 32553130
Adab P., Sh. Haroon, M. E O’Hara. Comorbidities and COVID-19. Better understanding is essential for health system planning. BMJ 2022; 377:o1431 http://dx.doi.org/10.1136/bmj.o1431
S. Genova, M. Pencheva, G. Kulinski. Histopathological Model of COVID-19 Pneumonia. Acta Morphologica et Anthropologica 2022; 29(1-2), 35-41. https://doi.org/10.7546/AMA.29.1-2.2022.06
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Sylvia Genova, Pencheva M., Petar Uchikov (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
